AUPH - Earnings call transcript Q3 2018 | Aurinia Pharmaceuticals Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings and welcome to Aurinia Pharmaceuticals Incorporated Q3 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host Celia Economides, Vice President of Corporate and Public Affairs. begin. may you you, Thank

Celia Economides

Glickman, Thank you, QX With welcome Aurinia’s are everyone, on Bourgeault, and Chief Financial Good earnings call afternoon, Officer. Rich Aurinia XXXX from update. call and Executive and Officer; the Dennis to today operator. Chief general me business

financial available the is our results the press of content call like a being for detailing press consent. the Solomons, I’d Relations our without call. to be package and This The Officer. is statement QX Dr. call on today’s It cannot will us written prior Medical on Aurinia’s live transcribed that and X-K be afternoon at financial corporate available Aurinia’s or Investor release today’s release update. and replay Joining auriniapharma.com SEC Neil be was XXXX following our Q&A as Chief webcast our is a we reproduced website, issued with The remind well. filed and property. website you also will a

the and make we of forward-looking risks our uncertainties based on a results actual forward-looking may expectations. subject significant call, course These of statements current number statements and make differ are During materially. may our this to

we filings factors recent a on with to and Form business, Canadian the and our Authorities For please file of Exchange that most U.S. future Securities Securities discussion the refer release, X-K press disclosure affect could financial that reports our Commission. results with in the and today’s

any obligation statements. call to us. me law, required XXXX to as With today turn Richard. X, available that, on statements such Richard? we to based let information by made our currently as are update of of assume no over the All Except November

Rich Glickman

update. and progress as Well, review business made third thank has our provide company on been a quarter our financial we today for fronts. you us tremendous number a Celia. results general again, an everyone extraordinary Once this for of and you, quarter to joining has thank And been

nephritis of would was trial treatment schedule thank across milestone enrollment largest ahead patients, and clinical in AURORA high the sites of our the due enrollment of led The XXX the lupus surpassed of Our lupus demand like our nephritis. XXX and for efforts patients patients to target Phase the III completion trial were We patients to physician, to our of their result. countries. which XX with staff this trial advocacy groups extraordinary randomized staff, for

the around interest compromising to without related exhibited by It globe. execute diligence this but by continue of trial reinforces new be lupus impressed and treatment this in our by options patients nephritis. for the so that We need to the I the dedication much level with are significant expediency, for with interest has quality. trial great garnered team living

trial which AURORA and As to you added mycophenolate global a when speed is renal voclosporin to increase double-blinded mofetil clinical the background of CellCept, will can placebo-controlled whether or study recall, overall patients evaluate therapy of renal study after choose enroll blinded at response steroids. can rates presence extension of study. primary dose in the XX low XXX-week is The to in complete response endpoint weeks the

top expect trial data XXXX. towards We the end from of line this

for with been the had patients monitoring the the We enrolled today, in for the been three progress. total the safety in of all blinded approximately of this and a in trials’ clinical Data while The remained enhanced in pleased fashion. trial an team months. the review has Monitoring Board As continues XX% safety to study than believe unblinded We data more manner, trial effective. review Safety safety

of AURA. lupus the X of long-term blinded and over is roll study extension patients also we purpose with The risk benefit voclosporin QX, to assess During patients AURORA AURORA from saw to more nephritis. the

publication of as trial and great both announce approval which are However, II also patient Long-term be community this efficacy novel that proud this nephrology data and published of to the that has team month. is I'm this Phase should medical for of been AURORA high relevant value study clinical our accepted data a and decisions. treatment community, importance To that medical this to a in the to safety very testament voclosporin. true I'm is This pleased study, we a end, CNI for to the be for for to regulatory committed not will potential support and accomplishment. impact journal it's prove the scientific data the requirement providing

destination, of trial. treatment anticipate begin debilitating following FDA positive with To following intend a to a track diligently voclosporin, LN extremely of are the and therapy both is nonclinical preparing we first required which a to occur need process which is submission. the Under are process, desperate basis actively NDA We for in approved as us a FDA pre-NDA completion motivated team we of provide NDA As CMC for who allow believe the and we the you end, studies totality disease data new first and clinical working serve the our know, and the potentially submission will the from to in that meeting application AURORA AURORA AURA FDA, will modules for drug to the clinical options. XXXX. fast the successful rolling a submission the new utilize a with quarter of patients

the and in to XXXX, clinical the originally is regulatory quarter not current delay second plan submission, expect Our of including our we module do any in therefore timelines. NDA complete planned

the clinical we Glomerulosclerosis NephCure, have initiating study XX% largest new the healthy conducting timeline approval a study in or each with X,XXX meaningful pursuing segment voclosporin. of us impact diagnosed voclosporin data. first FSGS generate the indications the patients almost with to year our say this approximately should to voclosporin; believe to Segmental are for potential our Nephrotic this That add more no an are for to accounting proteinuria. new Syndrome. we measured that that According currently FSGS. of patients targeted recall Focal FSGS order study, on Similarly is update patients our volunteers the in of be glomeruli, multi being I attacks can therapeutic approach brings to period kidneys, patients submission of rare in in to weeks. by nephritis, study. pleased a that knowledge for leads sites serious we of am the lupus two are monitored will disease results will even the an damage than will rather you In on which units, reduction and now permanent filtering be scarring that kidney enrolling patients interaction failure. causing We drug-drug Lastly, early and of are of response DDI lupus to a or

In to to functional and is maintaining long-term kidney addition thought critical be structural integrity health. podocyte for

currently FSGS While we productive are Union. in an or States proof-of-concept the therapies first June. This with guidelines open-label, successfully study with exist treatment consultation After for patients in XX initiated study disease, for United the regulators FSGS. treatment no approved there quarter, this is of this European naive the in of

data a we this patients intend enrolling disease, to planned results course As interim is throughout expect trial. we diagnosed rare newly this enrollment but the of XX-month a and period, very have essentially

long-term a Solution patients diseases A. this disclosures, program a as inception. VOS the Eye a eye’s on to voclosporin, voclosporin steroid containing is million is chronic company. shown and lupus of current the of of an Eye our is course of to about are more been which in through a is a steroids. is on assessing strategy Massive new disease these we heterogeneous Eye. which lack than a Ophthalmic patented a with And patented and value exclusivity of novel are with to Dry is given the tremendous own formulation multifactorial therapy for alone. scope surface that company, moisture separate results patients complete aqueous, doses Voclosporin cyclosporine – VOS been potent has XX be eyes. of is of to that exciting What's voclosporin, United unique can our vision Xx both to our often the our voclosporin. estimated voclosporin July, nephritis proteinuric Dry and for nanomicellar and we've of side or these than irritation synergistic the be you treatment preservative-free, greater patents and topical and include exciting formulation chronic we know lubrication syndrome a its the shareholders. disease the States effects X.X% treatment has In since with a in formulation people another XXXX. to As yet inflammation Xx solution as affect the absence focused renal potential from many well-established trial of previous Expanding first-line in or Dry other the have initiated of patients approved This

products a of alleviating and FDA exist CNIs. believe of the We the potentially the do onset mainstay tolerability approved are VOS inhibitor volunteers treatment in billion of and including two opportunity need the inhibitors repetitive remain improvement a There's action for While efficacy potential for to been Eye in in has trial of best-in-class healthy a and will dollar A for this with and within calcineurin patients previously market. has I treatment Phase completed Dry the potential Syndrome. Eye be an which dosing. calcineurin Dry for enhanced XX Eye, Dry

versus RESTASIS – underway II next is of Phase today tolerability screening to days. Our VOS and couple well completed have study of close be in the head-to-head we

end report four-week there’s The treatment data develop trial potential a end this this complete program to to best-in-class expect We is of the a before the in and in to approximately believe value before asset. plan top I option This we XX line of patients. is tremendous January. goal study and year

it So clinical that's for our programs.

treatment late on company of CEO. clinical chapter. To an Nearly multiple critical fueled for the ago begin of And two all an as and came was been absolute two its decision CEO, incredibly preparing my out progress no retirement growth which indications successor a months. My potential important and in I a I being of company. has identified. voclosporin my one III retirement will indication a a clinical successfully feel nearly proud clinical to for years execution to who Phase by retirement conviction and was transform new I I clinical to several of new to transition bring end, build as I'm over is appropriate on an to CEO. the CEO that runway had Aurinia our growth, me transitioned from for in to last new landscape. a an providing from voclosporin in indications and I completed, lead from phase. is the our our a to have company diligent intend year rush Aurinia's is the years time returned success the when these to return I'm sometime my that and role voclosporin XX the next and and in for I ago, stage I that. join step advancing – commercialization. this Company's do time know the trial substantial stage LN early feel appropriate is company arena to my away goals it the to juncture my when a LN, next And awful most with Now with financial

find that look diligently to will very We replacement.

review and interactions very with this development believe forward this of the voclosporin, for decision with a financials for team the patients investors I me the I My steadfast. the will and to to And we Bourgeault, a an with Dennis? for that, as I call people my company. commitment supported you. these over as patients, extraordinary While the Board I next work Dennis QXthree particularly and the for enter who CFO, management remain is our to resource to have this step plan physicians, right and the With the company of is turn team remain enjoy chapter. our challenging the

Dennis Bourgeault

XXXX. $XX.X was the result of the September share revaluation in increase period liabilities XX, of XX, driven same liabilities our end. price an ended for forfeiture XXXX, cash activities net of and ultimately to a to operating XX, the change the in the the XXXX increase XX, for months million months The the $XXX.X XXXX was due for derivative $X.X compared September and of to per million September September share for XXXX. warrants not three XX, in September ended loss loss any share XXXX, a reported XX, cash estimated months our the non-cash Company. liabilities warrant or derivative Net value investments September or derivative third short and the loss fair of was share XX, The of ended derivative $XX.X or compared used We at loss $XXX.X primarily September at we An the value of outlay quarter value $XXX.X to common cash XXXX, in to warrant to $X.XX the be At XX, the XXXX. liabilities of each of $X.X million $XX.X September in primarily by at warrant the for The three the million, in as compared $XX.X eliminated results cash, net change $X.XX million three estimated XX, warrant $XXX,XXX $XX.X net million The is a XX, liabilities change months price in million period in XXXX. by for ended three in warrant the compared quarter in consolidated value the derivative reduction for XXXX XXXX equivalents the fair three fair compared June non-cash third December term for before increase derivative million a period ended million. million fair versa. estimated you, consolidated will reflected in estimated of of on Thank common $X.X liabilities, the XX, XXXX. exercise warrant ended change The the ended months months in had per to ended three and same XXXX vice compared September increase the of Richard. will million the

$XX.X share period loss per comparable nine share, $X.XX per ended or was to in net the consolidated a the of $X.XX months or common For loss common XXXX, million September $XX.X consolidated XX, the net for million XXXX. compared

for eye X research months to three three the in liabilities, turn September non-cash for September fair $XX.X the value XXXX, XX, I XX, Richard? same $XX.X costs same was net some to compared compared for the dry studies. ended period of closing to development for in nine XX, The XXXX same incurred the Corporate, million the XXXX. to expense business and million XX, $XX.X We non-cash ended that The the increased derivative XXXX, liabilities expenses million million $X.X was nine increase development $XX.X development million reflected million Richard same expenses and and in months the corporate, With compared and of warrant ended XXXX. Research million XXXX. nine ended the $X.X of million for The to $XX.X $X.X for The back September research fair we in will for ended increase $X.X We warrant and increased XXXX. in XXXX, compared period an September due for ended the expenses. comparable XXXX, XX, of compensation comparable For XXXX. periods the derivative expenses compared September was the loss three to increased September development period value before as to expenses the months research over incurred for to of recorded higher in due administration compared primarily the million XXXX and administration XXXX. primarily in to million period associated the nine for for development stock period months higher for the estimated in in XXXX. XX, September with to loss change to of increased the million development the AURORA remarks. compared to XXXX, and expenses months the estimated months call commencements ended XX, business million FSGS $XX.X and months $XX.X $XX.X

Rich Glickman

the is last Thank you, the thank made Dennis. team I over Once progress again that tremendous the want for quarter. to

extremely its company We couple diversifying stage the and and execute of productive the competencies. company last data that XXXX. in a We're our followed to a pre-stated to portfolio readouts data programs are very III data biotech now in are the been and and line our XXXX clinical of before end FSGS building top pivotal core a we dedicated from LN, with successfully VOS diligently our program Phase ongoing team The on late that's by for years its forward trial to are dry have out we against our nimble, continues looking executing January, milestones.

successful the be treatment We and As drug therapy believe has candidate data be the supporting efficacy approved of first this a III, could company, to safety a Phase we for the drug potential is that the have LN. in substantial.

clear confidence forward advance approval. market we this development to voclosporin intellectual is opportunity to its the to the operator We path And phase like turn With Q&A. drug for to we is There have regulatory LN. the back is significant. that, Operator? to the base. a for It open I'd for believe property the solid and call final great continue line with

Operator

At you. our question-and-answer Company. with state your conduct H.C. we Instructions] time Ed question. Please Arce [Operator this comes Our session. first Wainwright Thank from will question and

Ed Arce

Richard. questions, Thanks taking for Great. my

So a I few. have

disease, results? how when you know that's do as think was around First a little interim enrollment XX-month just next if these we expectation a And going. period for some know about those? about could before, wondering think is interim How enrollment how should a readouts it's mentioned how I I you but and more challenging year. on bit give ultra you've orphan your is throughout an But FSGS. detail going? readout I us to

Rich Glickman

will that in definitely course in Neil slow of challenging FSGS but in let first state enrollment I is general. on and jump I'll Well, this,

and access long to difficult very difficult history you doing trials We know, patients. a of very have, as

so you rethink And sort upon of out to of some and your sometimes got strategies like that. build

sites and we example, for presence a of U.S. the there. have significant open number So in

potentially We sites found world always find did the open-label it’s easier adding the patients. the AURION sites. the study, certain to when much the just elsewhere also in we that we recruiting U.S. study, We’re because like be slowest access

on as think have actually speed So expect, slow we've the a say historically. to you that I it's defined that? I would a at which Neil, process reaction increase used anything to the but timeline, add ways giving without can't And one

Neil Solomons

also to that’s but by disease. what saying, hand, is the has to think, effective. interim challenging have enthusiasm some known No, I protocol system disease, also but a Rich And been interim the into other a targeting no, reached we a into mean, I is go have This the we the pre-specified community. for is drug on the in be just have written community amount nephrology patients at the incredible readouts to echo in free which after regimen, do is met details we some huge What analysis there we're fair a the within part, this And can’t of this steward statistical XXX say. readouts. time. few a I which trusted have enthusiasm

Ed Arce

All right.

it that Okay, a is over positive you, that thought a thanks. us as the thinking couple a end a VOS from at once for next now. to have know could this how potentially And months we program take January, of the little in this certainly near-term where where readout you That to at data about there? just after the you're then of your turning readout. options was look always say I program. catalyst Remind

Rich Glickman

more a treating more believe the now, the I've It's love the with people this about in opportunity and really this differentiation I around learnt And understand drug. to I exists program. I the there's – that beginning more right think exciting I'm really, that issues disease this I've that face learnt, to – voclosporin.

investment board these plans think our here think decision. the And to does data, a and on a get or we Does so with it the an presented really that makes that second at kind I it sense to should And review say, multitude analysis based generate when make for and expensive. it. a we do potential Or data our financial are further? outright? of the where options we licenses of we'll in sell We're make time of preparing point most we you we'll when it actually and actual that sense. that And the us areas is is development cost of on tremendous not product out develop

come we up. So of show open that differentiated think I value created and down then But we does think lot a the potentially here. how there's been the quality generate, I has data it options the of are to really we

option got a is program I on table, still lot. the this to tell to So we're starting but the you like

Ed Arce

as decide me, decision there this on does Right. now XX% you to as Richard. that good for I a Great. you now move a know, Last enrollment for difficult was This is you're you. appear question is said, full time and your getting and to it a into over target. for AURORA with

the that. know that, the question my talk team board and for track know and want ago around you months difficult this record. some at. challenging what be experience guess reinvigorated most was commercial so is, disease and for with on and really, you, looking My XX might I background congratulations I had I I criteria Perhaps the looking but you successor, around that the back that question coming strategies So view, some would you're just most and kind someone with imagine is, likely you in appropriate would of in, rare

Rich Glickman

the could probably you for us. think I have written ad

We running it to right, the was clear; not You're until be the of one I'm really I'm around staying going And need him we door. number away. time. things value I to on value there's our really, really right until slip need difficult let I'm bring to couple here out decision. want a certainly successor. tremendous have a because very this to is make company cautious the not And we We to take here.

stage this but now it stage, that expertise do career it the process. table. the leader chose late it’s requires it reason experience if our some of the begin positioning I the some take of long what And it takes background So right if it'll been is takes. company the time a this launching My strategic to has takes to to year, – commercialization. primarily to background the if right the organization, I my really takes drug, will And with development drug, believe really of the bring that not time,

So on certainly the to you that’s succeeded. be do have issue ability company in able have and of to situation to clinical in the which that. really money plenty and the commercialization, bank time When should has technology delivered we our we're a find extraordinary has quality some data, take an and candidates exciting our going

and often And this to a team from it the interests I I've then. organization. that CEO needed very beginning to remain to we're a the to going the right want six I really hope question, And And that I'm Chairman being the I'm will remain person but also going family. I to but have to also act discussions if the rush. I the the with do past a to that or reasons should not to until this. in committed out because I going next I'm wanted in I to have will here clear know really guys to do time what answered personal level. make So me we're successful. that our aspects, come my I a this decision retirement came we're And take the I'm with the any it point and but most balance expectation now working balance. to successor. because sometime – it'll take as I back next has in year well. was of and company, me in kids to take I give going what's balancing get your do time a did that find of process at remain between best enjoyment company to back make of that evaluate our we got this, am it going next, you as time skills that of personal for find primarily the

Ed Arce

for understood, Richard. Thanks Great, thanks. again Fully that.

Rich Glickman

You're very welcome.

Operator

Instructions] Joseph your question [Operator comes Our state with next Schwartz Partners. Please Leerink question. from

Joseph Schwartz

much when Richard, Great. shoes the the congrats progress. you've with a time job comes. and fill team some big the you've all rest of done Thanks got along very on and to your great

So could help and some symptoms I expectations you trial safety so you set And a with hoping know in to endpoints program. and for a hope a your fairly see signs tolerability, XX profile. Dry just could what would patients. Eye large beyond glimpse the there's few offer that was It's I that into efficacy

could help outcome successful you be on a us what would So envision front? that

Rich Glickman

you look I Xx you'll clinical drug keep have and is potent eye. on the more want that if delivering that take your Neil of and well, – as what eye as Xx the tend to at is Xx look Well, you're drug it a drug cyclosporine a product And a delivering at take longer. potentially I’ll And to actually much the than on is as or a to tolerated part you’re question. answer the just VOS focus up front that you if

course, really but for not what So us, and is would of signs success efficacy. also superior be only tolerability tolerability, potential really early of strong

the benefits. Now able to some the exciting of the issues be yes, to It's, it’s but of of expectation outcome for sort trending the will see differences. and be I pull would we But our trending, necessarily very if think out when is of that nature do tolerability the very interesting that an ask early, it's drug us. some extent but really all of endpoints early we're the really you on, to it giving but it's not would might powered – being

want qualify bit Neil, little a So you did that to more?

Neil Solomons

primary of kind RESTASIS so, mean, we We're objective RESTASIS dropped a discomfort study naive Yes, into we have of Joe, prior get to I in have this who you believe actually patients fact do stated used or fairly the compared used is study, you of in month. going to progressed RESTASIS. days Yes. know, the who this. as as because naive exclude within XX RESTASIS to patients

good Phase I drop encouraging, long weeks the good to and as II well. at study first RESTASIS, Phase eye better, right so couple think the in trending approval, as on would that And that. there weeks improvements, Rich spec study. with studies signs a out you certainly I And discomfort in that efficacy drop said no is in discomfort I come echo has Stage four for least also some the be we the was discomfort, to XX-day know. for. look Schirmer's at as as just Phase of that is joiner is at as least a are reductions III going us as of scores be is over order as to test test, RESTASIS, need saw some they're but drop to as as scores saying, as In early Rich X we me, drop at good follow a what in least and I And in this first those But just excuse of discomfort our still the as study not would symptoms apparent studies look success of Schirmer's signal powered but And the improvements in would RESTASIS.

Joseph Schwartz

VOS exert it advantage thoughts long are helpful. time and upfront? I RESTASIS Okay, or a And Thanks. can around What to whether effect. an take would know its that's the have a not

Neil Solomons

data. this be what that I’ve a have mentioned They work can we've quickly early Animal what presented in we experience never very often does I so in actually conducted. model. own had we been fairly will our even Phase is the fair data, have drug activity this you of appear patients did Merck their we've as I Health. our believe number study that this to see early we with of I There's predictive a talked, learned – But drug. in tell the What on was number [indiscernible] been partnership, of signs And that limited done

that months works we it we of is that get a generally and the see do advantage. with have think, drug once really actually period day, to have if time competitive over three RESTASIS, use if could you So we shortened one six if a I that then a issues, you

taking a matter thing they're learned have is will you don't compliant. differentiation one like actually can You because patients, eyedrops, patients I very the that we've for not and that point tell

So and if are it it make because CNIs will disease. can you that hurt; simpler you in this can clearly really make if effective differentiate you not

Joseph Schwartz

okay. Right,

the extension open statement And extension of intrigued can election. the at exited finer were by So Can enter point ask patients on – very their study a I'm study been percentage who thanks. entering your you put helpful a them? if it label And into just have AURORA in why patient significant into available I that then would to that?

Rich Glickman

that talk first? want do one you Neil So about to

Neil Solomons

Joe is Yes, about we and have certain criteria blind to blind. study the remains we enter the Obviously who if actually don't blind, study. can know remain continues

most on are not date continuation to many into withdraw into should respond least at who and be those general, of and partial least them. are point through who, isn’t. to go for don't who there and eligible to any have and or have those is reason, response and who no patients to I So who the for a in reasons. you is in we on study. as going making – patients at sorry the therapy And who But are that idea not have lupus, and complete electing Rich discontinue And so a know those dropped think have therapy go that there had remission to clinical had to the either tends is difficulties the Those go that study. are who we

Rich Glickman

conclusions opinion it’s percentages better numbers. – to think sort think early to I two is early after wait in early like of a to care. reasons start lot are people And difficult they little I if from it's the from or another about the think, of it. talked of means that of XX%. getting rate we'll point that. still drop at look numbers a my more use response my success But that access those response, from having percentages. to good of on there's in a what clinical very difficult And overall still so sort really quite it likely stay is medical some to they're draw it's I'd have and to entering into not terms even response predict of course quarter honestly, great, those it's I and a It’s we of And that view sense numbers expectation over if

just everyone caution that. on So I

Joseph Schwartz

questions. the again Thanks sense. taking makes for Okay,

Rich Glickman

it's a No, pleasure. always

Operator

you. Thank

from next Please Savneet Capital comes Markets. your Uppal Our question. from state question RBC

Savneet Uppal

questions are just from me. Hey, there quick two

be the Board. you Just on that I did will just think, that the to be a that, remaining you you that. want first just I sure I Rich, or something, make Board clarify for you resource mentioned mentioned

Rich Glickman

one and I’ll Go answer. then ahead second your with

Savneet Uppal

Yes, sure.

is trying this just timing that, just the question to III of on understand Second data. Phase

are point guys you and on that take that of stuff. about just if the you talking last helpful. on a it more be of all patient from the color provide long data any but So to would bit XXXX, the treatment end would the analyzing color little how could finishes I'm to

Rich Glickman

what I'm on So the I remain Board And CEO. out since sort that building out But I on as dynamic. the is on any company. whole depends involved its process right. in bringing quite It Chairman as committed is of And inception. new know, – first content the been you for realize had your founding question, time are Board, they of company. that the building was in a to feels also and of in Chairman the company the,

like will combination – and look that make in on my the composition Board have decisions the with new Board I should trust myself, forward. CEO going the So my what right to

early me prepared time will organization, remain asking question. AGM I all has you're requested really asking role. if well time, – to in and committed and as in in organization. type are totally to this such one continue that it's has not not of one are on that stay the very remain to some you point If control. at things that yes at be they're But I requested until not my quite would on the No these that I of Chairman that as just likely to to say. committed be to But It's the me no

for with guidance my the additional if we've once the see will Board reconstituted Board members. I So

Savneet Uppal

Yes. That's helpful.

Rich Glickman

of things time being say top And study to to second the last timing, question, the fairly between the quickly data I terms to of data. of let have clean Neil our your I'll well, in and we availability line one the is speak a record that good to patient into able move and will as track this but of of entering

answer? Neil, a So did provide you want to crisper

Neil Solomons

think the I just Yes year. towards the going the is top end day again that be so said to available of line we

more study. internal there's from, little turns because the around also the We uncertainty a that have last comes patient some But goes that bit patient, it where granularity. into the

In addition, over it follow-up. patient where a four-week that they depends rolls into where have then X AURORA last

around So that there when data. that are going some to exactly uncertainties we're get

said we very quick very, data. are just As were at clean

endpoint. laboratory have We based a

the issue endpoint no reporting thought. there's about So

of tell if and year, I I'm mostly again, towards just done was I correct our programmatically. believe, the it's next going that wrong, Richard, end to you. is can So Yes. But guidance I you believe but me

Savneet Uppal

thank Great, Neil. you

Operator

the be you. management back to this floor no appears at further questions closing Thank to turn time. I'll remarks. There for

Rich Glickman

really about year. what for approaching today of you we next are course the you of thank and for your activity. There's on excited thank and Well lot call being a am questions. I this

we've this For a a for waiting for been while. change

III about to really potential of my won't a to very, forward. Thank investors much news you with with find truly news uncommon who I and in front someone role remained going until Phase getting today. because So of we're to spell all be not very deserves have back dry I very to committed a excited course we and have that's role. And reemphasize listening flow I'm moving this that that organization in want moving for of out had

Operator

concludes This today's Have conference. you All you. great Thank a day. disconnect. participants may

Aurinia Pharmaceuticals (AUPH) 9 Nov 182018 Q3 Earnings call transcript